Challenges in developing endpoints for type 1 diabetes intervention studies

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 8, 2009, Pages 694-704

  Cernea, Simona ^a   Raz, Itamar ^b   Herold, Kevan C ^c   Hirshberg, Boaz ^d   Roep, Bart O ^e   Schatz, Desmond A ^f   Alexander Fleming, G ^g   Pozzilli, Paolo ^a   Little, Randie ^h   Schloot, Nanette C ⁱ   Leslie, R David G ^j   Skyler, Jay S ^k   Palmer, Jerry P ^l  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b HEBREW UNIVERSITY   (Israel)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ASTRAZENECA   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g Kinexum   (United States)

^h University of Missouri   (United States)

ⁱ LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^j Institute of Cell and Molecular Science   (United Kingdom)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

C peptide; Intervention studies; Type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

AUTOIMMUNITY; CELL FUNCTION; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES CONTROL; DIET RESTRICTION; DRUG EFFICACY; GLUCAGON STIMULATION TEST; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLIC REGULATION; MIX MEAL TOLERANCE TEST; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; STANDARDIZATION; WORKSHOP;

C-PEPTIDE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; ENDPOINT DETERMINATION; HUMANS; INSULIN; INSULIN-SECRETING CELLS; INTERVENTION STUDIES; ORGAN SIZE;

EID: 73349120926     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1002     Document Type: Review

References (76)

1. Palmer JP, Fleming GA, Greenbaum CJ, et al. ADA Workshop Report: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function; report of a ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
2. Greenbaum CJ, Harrison LC. Immunology of Diabetes Society; Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003; 52: 1059-1062.
3. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial; a randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
5. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
6. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al, The Type 1 Diabetes Trial Net Research Group and The European C-peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966-1971.
7. Robertson RP. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 2007; 56: 2420-2424.
8. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984; 33: 486-494.
9. Polonsky K, Frank B, Pugh W, et al. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 1986; 35: 379-386.
10. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988; 81: 435-441.
11. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
12. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988; 81: 435-441.
13. Breda E, Toffolo G, Polonsky KS, Cobelli C. Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times. Diabetes 2002; 51(Suppl. 1): S227-S233.
14. Cutfield WS, Jefferies CA, Jackson WE, Robinson EM, Hofman PL. Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children. Pediatr Diabetes 2003; 4: 119-125.
15. Altuntas Y. A mathematical model for pattern of change in beta-cell reserve and factors affecting residual reserve within the first 2 years of type 1 diabetes. J Endocrinol Invest 2002; 25: 987-992.
16. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998; 47: 324-330.
17. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation 1993; 55: 186-192.
18. Bending JJ, Ogg CS, Viberti GC. Diabetogenic effect of cyclosporin. Br Med J (Clin Res Ed) 1987; 294: 401-402.
19. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
20. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006; 55: 3238-3245.
21. Sherry N, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 mAb by enhancing recovery of beta cells. Endocrinology 2007; 148: 5136-5144.
22. Clarson C, Daneman D, Drash AL, Becker DJ, Ehrlich RM. Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve. Diabetes Care 1987; 10: 33-38.
23. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006; 49: 261-270.
24. Caprio S, Plewe G, Diamond MP, et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 1989; 114: 963-967.
25. Alejandro R, Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997; 46: 1983-1989.
26. MadsbadS, KrarupT, FaberOK, BinderC, RegeurL. The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1982; 22: 16-20.
27. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther 2006; 8: 165-173.
28. Pozzilli P, Visalli N, Buzzetti R, et al, IMDIAB Study Group. Immunotherapy Diabetes. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. Metabolism 1998; 47: 1205-1210.
29. Komulainen J, Knip M, Lounamaa R, et al, The Childhood Diabetes in Finland Study Group. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. Diabet Med 1997; 14: 532-537.
30. Petrone A, Galgani A, Spoletini M, et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev 2005; 21: 271-275.
31. Weets I, Truyen I, Verschraegen I, et al, Belgian Diabetes Registry. Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia 2006; 49: 1158-1162.
32. Picardi A, Visalli N, Lauria A, et al. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2006; 38: 668-672.
33. Törn C, Landin-Olsson M, Lernmark A, et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000; 85: 4619-4623.
34. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004; 53: 426-433.
35. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the peri-onset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008; 31: 2188-2192.
36. Nordwall M, Ludvigsson J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev 2008; 24: 472-479.
37. Pfleger C, Mortensen HB, Hansen L, et al, Hvidøre Study Group on Childhood Diabetes. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008; 57: 929-937.
38. Pfleger C, Kaas A, Hansen L, et al, Hvidøre Study Group On Childhood Diabetes. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 2008; 128: 57-65.
39. Schloot NC, Meierhoff G, Lengyel C, et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007; 23: 276-285.
40. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763-1769.
41. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007; 23: 286-291.
42. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238-246.
43. Pitocco D, Crino A, Di Stasio E, et al, IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 2006; 23: 920-923.
44. Wiedmeyer H, Rohlfing C, Tennill A, et al. Evaluation of the stability of C-peptide in plasma and serum: comparison of 3 different methods. Clin Chem 2004; 50: A110.
45. Wiedmeyer HM, Polonsky KS, Myers GL, et al. International comparison of C-peptide measurements. Clin Chem 2007; 53: 784-787.
46. Little RR, Rohlfing CL, Tennill AL, et al. Standardization of C-peptide measurements. Clin Chem 2008; 54: 1023-1026.
47. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007; 23: 269-275.
48. Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, doubleblind, phase II trial. Diabetes Metab Res Rev 2007; 23: 292-298.
49. Ludvigsson J, Faresjö M, HjorthM, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-1920.
50. O'Leary LA, Dorman JS, LaPorte RE, et al. Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies? Diabetes Res Clin Pract 1991; 14: 183-190.
51. Barker JM, Goehrig SH, Barriga K, et al, DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004; 27: 1399-1404.
52. Shah SC, Malone JL, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl JMed 1989; 320: 550-554.
53. Crinó A, Schiaffini R, Ciampalini P, et al, IMDIAB Group. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005; 18: 749-754.
54. Herold KC, Gitelman S, Greenbaum C, et al, Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132(2): 166-173.
55. FDA Guidance for Industry. Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. Available from: http://www.fda.gov/cder/guidance/7630dft.pdf [accessed on April 14 2008].
56. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988; 37: 81-88.
57. DCCT Research Group. The relationship of a glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
58. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on themicrovascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
59. Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007; 7: 303-308.
60. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev 2005; 204: 232-249.
61. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45: 926-933.
62. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity 2008; 41: 11-18.
63. Baschal EE, Aly TA, Babu SR, et al. HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/ DR4-DQB1*0302 DAISY population. Diabetes 2007; 56: 2405-2409.
64. Kupila A, Muona P, Simell T, et al, Juvenile Diabetes Research Foundation Centre for the Prevention of Type I Diabetes in Finland. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 2001; 44: 290-297.
65. Hoppu S, Härkönen T, Ronkainen MS, et al. IA-2 antibody isotypes and epitope specificity during the prediabetic process in children with HLA-conferred susceptibility to type I diabetes. Clin Exp Immunol 2006; 144: 59-66.
66. Barker JM, Barriga KJ, Yu L, et al, Diabetes Autoimmunity Study in the Young. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89: 3896-3902.
67. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48: 460-468.
68. Roep BO. Islet autoreactive CD8 T-cells in type 1 diabetes: licensed to kill? Diabetes 2008; 57: 1156.
69. Sherr J, Sosenko J, Skyler JS, Herold KC. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008; 4: 334-343.
70. Sosenko JM, Palmer JP, Greenbaum CJ, et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006; 29: 643-649.
71. Lo SS, Hawa M, Beer SF, Pyke DA, Leslie RD. Altered islet beta-cell function before the onset of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 277-282.
72. Vardi P, Crisa L, Jackson RA, et al. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulindependent) diabetic patients. Diabetologia 1991; 34: 93-102.
73. Mrena S, Savola K, Kulmala P, Akerblom HK, Knip M, Childhood Diabetes in Finland Study Group. Staging of preclinical type 1 diabetes in siblings of affected children. Pediatrics 1999; 104: 925-930.
74. Dotta F, Eisenbarth GS. Type I diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction. Clin Immunol Immunopathol 1989; 50: S85-S95.
75. Schatz D, Cuthbertson D, Atkinson M, et al. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus-a new surrogate measure of non-progression? Pediatr Diabetes 2004; 5: 72-79.
76. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.